AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04607759 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: nutraceutical
Description: Subjects will consume two capsules for eight weeks
Study NCT05714930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treat-to-target as a new treatment concept
Description: After trial initiation, the study personnel in the intervention centers will receive a training on T2T and shared decision making (SDM). Patients in the intervention centers will receive 6-weekly visits for at least 24 weeks with therapeutic adjustments to achieve remission. In case of stable remission for 6 weeks at week 24, the patients switch to 12-weekly visits until the end of the trial at week 120. In case of flare, the patient switches to 6-weekly visits for 24 consecutive weeks. Pharmaceutical treatment decisions will be guided by current treatment standards and will be taken in accordance with SDM between patients and treating physicians.
Study NCT06788730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transtheoretical Model Based Healthy Internet Use Programme Intervention Supported by Mindfulness Exercise Applied to Adolescents
Description: Transtheoretical Model Based Healthy Internet Use Programme Supported by Mindfulness Exercise will be carried out as one session per week for 8 weeks. The training programme will be carried out by dividing the students into 2 groups (the first group is 18 and the second group is 19 people). The training programme will be applied to the groups two days in the same week at the times determined by the guidance teacher. Interventions will be applied to the intervention group with trainings, homework applications and interventions to increase healthy internet use.
Study NCT05690386 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Description: Once-weekly subcutaneous injection of Lonapegsomatropin
Study NCT05690386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Somatropin
Description: Once-daily subcutaneous injection of Somatropin
Study NCT05921643 — intervention group
Intervention type: DEVICE
Intervention: verre bioactif 45S5 GlassBONE
Description: All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
Study NCT05921643 — intervention group
Intervention type: DEVICE
Intervention: verre bioactif S53P4 Bonalive
Description: All patients will benefit from surgical management for a first stage cholesteatoma in the operating room under general anesthesia. The surgical technique (closed technique) is the reference technique for the management of cholesteatoma in adults. It involves a cartilaginous removal to reconstruct the attical region. Then a filling material is used to fill the mastoid (GlassBONE™ or Bonalive™), and above all to stabilize the cartilaginous fragment to prevent a recurrence. The mastoid filler used is left to the discretion and habits of the surgeon.
Study NCT05196399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan (Formulation A)
Description: A single oral dose of 25 mg.
Study NCT05196399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan (Formulation B)
Description: A single oral dose of 25 mg.
Study NCT04489160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Inhibitor, Human
Description: 6000 IU C1-INH
Study NCT04489160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study NCT06126380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-1501
Description: AT-1501 20 mg/kg administered every 3 weeks IV + MMF 1000 mg PO twice daily (BID) or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO once daily (QD) or equivalent
Study NCT06126380 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus dosed PO BID with the dose titrated to maintain a trough concentration of 6-8 ng/mL+ MMF 1000 mg PO BID or MPS 720 mg PO BID + Corticosteroids 5 mg of prednisone PO QD or equivalent
Study NCT05742945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate lymphatic reconstruction
Description: Breast cancer patients receive axillary lymph node dissection and immediate lymphatic reconstruction
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avelumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axitinib
Description: Given PO
Study NCT05327686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Given PO
Study NCT05327686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib
Description: Given PO
Study NCT05327686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Given PO
Study NCT05327686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05327686 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy
Description: 42 Gy in 3 fractions
Study NCT04367506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BecomeAnEX
Description: This research study is focused on a smoking cessation program called BecomeAnEx. We are studying how to adapt BecomeAnEx for people with a mental health disorder who want to reduce or quit their tobacco smoking. BecomeAnEx includes a website that provides education about smoking and quitting. It also has a text messaging program that delivers personalized information. Persons in the program have access to real-time digital coaching with a remote coach who has experience helping people quit smoking. In addition, the program has an on-line community of current and former smokers that can provide support and encouragement.
Study NCT04367506 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
Study NCT04367506 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care represents what hospitalized psychiatric patients normally receive in terms of smoking cessation: brief individual counseling, NRT during the hospital stay and a prescription for NRT at discharge (consistent with standard hospital procedures), and referral to the MD quitline.
Study NCT05076591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM2902
Description: a recombinant bispecific monoclonal antibody with high affinity to the dual targets, HER2 and CD47
Study NCT06097013 — intervention group
Intervention type: OTHER
Intervention: Routine clinical rehabilitation
Description: Routine clinical rehabilitation
Study NCT06788652 — intervention group
Intervention type: BIOLOGICAL
Intervention: Lisocabtagene maraleucel
Description: According to US Prescribing Information
Study NCT06789107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab 9ug
Description: Blinatumomab for Refractory/Active Systemic Lupus Erythematosus. Patients will receive two 5-day cycles of Blinatumomab (5 µg/m²/day, maximum dose 9 µg/day), administered intravenously. The second cycle will begin on the first day of the third week following the first cycle.
Study NCT06789003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted exercises
Description: Patients will have 3 sessions a week: 1 strengthening session and 2 endurance sessions.~For each session, patients will choose the exercises to be performed from the exercise booklet or the videos and records their observations in the patient notebook.~Depending on the treatment plan, patients will have alternating supervised (in hospital) and unsupervised (at home) APA sessions, in order to follow the rhythm of their visits to the department.~Each session will last 45 minutes with a medium intensity according to the Borg scale.
Study NCT06789003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Patients will not be practising adapted exercises as part of the study. They will be treated with chemotherapy according to standard practice.
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality of Life questionnaire
Description: QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quality of Life questionnaire
Description: QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire of Fatigue
Description: Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire of Fatigue
Description: Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity questionnaire
Description: Questionnaire (IPAQ) at baseline and after transplantation
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity questionnaire
Description: Questionnaire (IPAQ) at baseline and after transplantation
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical condition
Description: Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation
Study NCT06789003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical condition
Description: Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation
Study NCT06788873 — intervention group
Intervention type: OTHER
Intervention: Data comparison
Description: For each participant, information will be collected on:~* Gestational age at the time the cerclage was performed~* Parity~* Age~* BMI~* Ethnicity~* Number of preterm deliveries~* Gestational age of previous preterm deliveries~* Previous uterine and/or cervix surgery (previous cerclage, conization, metroplasty, or other)~* Type of cerclage performed~* Operative times~* Days of hospitalization~* Surgical complications~* Gestational age at the time of delivery~* Mode of delivery (spontaneous, operative or cesarean)~* Infant's weight at birth~* Apgar at 1' and 5' minute~* Ph newborn~* Possible admission to neonatal intensive care unit.
Study NCT06789874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Saline
Description: Intralesional Saline injected in scars
Study NCT06789874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 35% trichloracetic acid peel
Description: 35%Trichloracetic acid peel was applied to scars monthly for 3 months
Study NCT06788795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Device with Phone App
Description: This is the intervention where the patients will be given both the wearable dehydration device as well as the phone app
Study NCT06788795 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device without Phone App
Description: This is the intervention where the patients will receive the device alone
Study NCT06788392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reminiscence therapy
Description: Reminiscence Therapy is a supportive care model that has been used in recent years and increases life comfort.
Study NCT06789120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization
Description: In the study, the Graston device will be applied to the plantar flexor muscles of the patients. The medial and lateral gastarosoleus muscles and tendon will be applied deeply for 3 minutes, and the soleus muscle will be applied deeply for 90 seconds.
Study NCT06789731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Description: Mindfulness meditation will be facilitated by a seasoned mindfulness practitioner. Participants will be guided through a loving kindness meditation adapted to apply to college communities and designed to help increase a sense of interconnectedness among their college community. They will also learn how to deconstruct feelings of anxiety and/or depression into sensory, emotional, cognitive, and behavioral components.
Study NCT06789731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: In the psychoeducation arm, participants will receive information related to creating connections with campus community and managing anxiety and/or depression through a presentation. They will also receive information on resources for connecting with their community and treating anxiety and/or depression.
Study NCT06788925 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patients support with survival coverage
Description: Following calls to emergency medical services, handled by the ground SMUR/SAMU or the air SMUR (HéliSMUR), the operator collects essential information on the nature of the incident and the apparent condition of the injured. A medical team is thus mobilized on site. It takes over from the rescue team (e.g. the SDIS fi refi ghters) who are generally the fi rst to arrive on the scene.~Eligible patients will be randomly assigned consecutively to one of two groups: control (use of the survival blanket) and experimental (use of the Therm'Up breastplate).~Any traumatized person at risk of hypothermia or in hypothermia in a pre-hospital environment, having given verbal consent to participate in the study and meeting the inclusion criteria
Study NCT05957874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined package program
Description: Combined package program content:~* Training: A one-week sleep hygiene training will be given to the experimental group. The training will take an average of 30 minutes for three consecutive days and a training booklet will be provided. In addition, two posters will be prepared to hang in the classroom. In one of the posters, a sleep hygiene rule will be placed at each hour using the clock order. In the other poster, good and bad sleep habits will be placed in the form of do-do.~* Task Flower: Tasks that will facilitate the transition to weekly sleep will be given to the children of the experimental group. Tasks are applications to be done within 30-60 minutes before going to bed. After the tasks, the children will perform their daily sleep routine and go to sleep.~* Notifications: As part of using technology positively, reminders will be sent to families every day for two weeks via a social media tool. These warnings will include sleep hygiene principles.
Study NCT04629729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: Experimental Interventional Therapy
Study NCT05498857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular ephedrine
Description: Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
Study NCT05498857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intramuscular ephedrine
Description: Patients will receive prophylactic intramuscular ephedrine plus standard spinal anesthesia
Study NCT05498857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
Study NCT05498857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive prophylactic intramuscular saline plus standard spinal anesthesia
Study NCT06788925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patients support with active thermic jacket
Description: The intervention Description is exactly the same, except that the patient will be given a ThermUp jacket
Study NCT06183437 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stopping Heart Failure Medication(s)
Description: This group will stop their heart failure medication(s) under the supervision of the study team.
Study NCT06787586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATTO-1310
Description: ATTO-1310 Attobody
Study NCT06787586 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ATTO-1310 Placebo
Description: Placebo preparation to match ATTO-1310 Dose
Study NCT06789380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Schema therapy
Description: Schema therapy (ST) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bamelis et al., 2014; Sempértegui et al., 2013; Arntz et al., 2022). Eligible programs must adhere to the minimum standards described in the evidence-based literature. ST is an integrative treatment method, originally rooted in cognitive theory, but with additional influences from Gestalt, psychodynamic, and experiential methods. Schema therapy programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions and/or a duration of 12 to 24 months. In addition, in order to be eligible, a schema therapy program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
Study NCT06789380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mentalization-based treatment
Description: Mentalization-based treatment (MBT) is an evidence-based, fully manualized, specialist form of psychotherapy for personality disorders (Bateman \& Fonagy, 2008; Bateman \& Fonagy, 2009; Laurenssen et al., 2018; Juul et al., 2023). MBT is rooted in psychodynamic and attachment theory and aims to alter personality pathology by improving mentalizing and enhancing epistemic trust. Eligible programs must adhere to the minimum standards described in the evidence-based literature. MBT programs may differ in intensity and duration, even at the same site, but must include a minimum of either 40 sessions or a duration of 12 to 24 months. In additon, in order to be eligible, an MBT program must be of higher intensity or longer duration than the generalist treatment (GIT-PD) offered at the same site.
Study NCT06789380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline-informed treatment for personality disorders
Description: GIT-PD is a non-theoretical and non-methodological approach, based upon principles derived from common factors across evidence-based treatments for PD. GIT-PD has a flexible approach, enabling tailoring treatment to clinical needs of different types of patients. The treatment duration (start-end) is 12- 18 months. The treatment consists of three distinct phases. First, an assessment phase. Second, a modular treatment phase that offers either group or individual interventions. Third, a follow-up phase with limited treatment and focus on relapse prevention. In order to be eligible, GIT-PD should be less intensive than specialist psychotherapies offered in the control arm at the same location (i.e. MBT or ST). GIT-PD will not include evidence-based psychotherapy for personality disorders as described in previous RCTs.
Study NCT06789991 — intervention group
Intervention type: DEVICE
Intervention: electromyography
Description: electromyographic activity of posterior oblique sling muscles will be measured
Study NCT06789276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supine position
Description: For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in either the supine position.
Study NCT06789276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lateral decubitus position
Description: For patients scheduled for thoracoscopic surgery, thoracic paravertebral nerve block was performed under ultrasound guidance. After the injection of the drug, patients were positioned in the lateral decubitus position with the puncture side up.
Study NCT05405088 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Pain Sensitive Questionnaire (PSQ) Corah's Dental Anxiety Scale (CDAS) Pain Catastrophizing Scale (PCS) Gender Eye color Hair color Blood group
Study NCT06788366 — intervention group
Intervention type: DRUG
Intervention: Immunotherapy
Description: First-line regimen according to clinical practice